Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
1.
Sci Rep ; 11(1): 15131, 2021 07 23.
Article in English | MEDLINE | ID: mdl-34302034

ABSTRACT

Metabolic dysfunction in chondrocytes drives the pro-catabolic phenotype associated with osteoarthritic cartilage. In this study, substitution of galactose for glucose in culture media was used to promote a renewed dependence on mitochondrial respiration and oxidative phosphorylation. Galactose replacement alone blocked enhanced usage of the glycolysis pathway by IL1ß-activated chondrocytes as detected by real-time changes in the rates of proton acidification of the medium and changes in oxygen consumption. The change in mitochondrial activity due to galactose was visualized as a rescue of mitochondrial membrane potential but not an alteration in the number of mitochondria. Galactose-replacement reversed other markers of dysfunctional mitochondrial metabolism, including blocking the production of reactive oxygen species, nitric oxide, and the synthesis of inducible nitric oxide synthase. Of more clinical relevance, galactose-substitution blocked downstream functional features associated with osteoarthritis, including enhanced levels of MMP13 mRNA, MMP13 protein, and the degradative loss of proteoglycan from intact cartilage explants. Blocking baseline and IL1ß-enhanced MMP13 by galactose-replacement in human osteoarthritic chondrocyte cultures inversely paralleled increases in markers associated with mitochondrial recovery, phospho-AMPK, and PGC1α. Comparisons were made between galactose replacement and the glycolysis inhibitor 2-deoxyglucose. Targeting intermediary metabolism may provide a novel approach to osteoarthritis care.


Subject(s)
Cell Respiration/physiology , Chondrocytes/metabolism , Mitochondria/metabolism , Osteoarthritis/metabolism , Aged , Animals , Cartilage, Articular/metabolism , Cattle , Cells, Cultured , Female , Glucose/metabolism , Glycolysis/physiology , Humans , Interleukin-1beta/metabolism , Male , Matrix Metalloproteinase 13/metabolism , Nitric Oxide/metabolism , Oxidative Phosphorylation , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Reactive Oxygen Species/metabolism
2.
J Orthop Res ; 38(5): 1122-1131, 2020 05.
Article in English | MEDLINE | ID: mdl-31774188

ABSTRACT

Using in vitro models, we previously reported that 4-methylumbelliferone (4-MU) blocked many of the pro-catabolic features of activated chondrocytes. 4-MU also blocked safranin O loss from human cartilage explants exposed to interleukin 1ß (IL1ß) in vitro. However, the mechanism for this chondroprotective effect was independent of the action of 4-MU as a hyaluronan (HA) inhibitor. Interestingly, overexpression of HA synthase 2 (HAS2) also blocked the same pro-catabolic features of activated chondrocytes as 4-MU via a mechanism independent of extracellular HA accumulation. Data suggest that altering UDP-sugars may be behind these changes in chondrocyte metabolism. However, all of our previous experiments with 4-MU or HAS2 overexpression were performed in vitro. The purpose of this study was to confirm whether 4-MU was effective at limiting the effects of osteoarthritis (OA) on articular cartilage in vivo. The progression of OA was evaluated after destabilization of the medial meniscus (DMM) surgery on C57BL/6 mice in the presence or absence of 4-MU-containing chow. Mice fed 4-MU after DMM surgery exhibited significant suppression of OA starting from an early stage in vivo. Mice fed 4-MU exhibited lower OARSI scores after DMM; reduced osteophyte formation and reduced MMP3 and MMP13 immunostaining. 4-MU also exerted pronounced chondroprotective effects on murine joint cartilage exposed to IL1ß in vitro and, blocked IL1ß-enhanced lactate production in cartilage explants. Therefore, 4-MU is effective at significantly reducing the loss of proteoglycan and reducing MMP production both in vitro and in vivo as well as cartilage damage and osteophyte formation in vivo after DMM. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res. 38:1122-1131, 2020.


Subject(s)
Arthritis, Experimental/drug therapy , Hymecromone/therapeutic use , Osteoarthritis/drug therapy , Animals , Drug Evaluation, Preclinical , Female , Male , Mice, Inbred C57BL
3.
J Biol Chem ; 294(47): 17799-17817, 2019 11 22.
Article in English | MEDLINE | ID: mdl-31619518

ABSTRACT

Hyaluronan is a critical component of articular cartilage and partially helps retain aggrecan within the extracellular matrix of this tissue. During osteoarthritis, hyaluronan and aggrecan loss are an early sign of tissue damage. However, our recent attempts to mimic hyaluronan loss with the hyaluronan inhibitor 4-methylumbelliferone (4MU) did not exacerbate arthritis-like features of in vitro models of arthritis, but surprisingly, caused the reverse (i.e. provided potent chondroprotection). Moreover, the protective effects of 4MU did not depend on its role as a hyaluronan inhibitor. To understand the molecular mechanism in 4MU-mediated chondroprotection, we considered recent studies suggesting that shifts in intracellular UDP-hexose pools promote changes in metabolism. To determine whether such metabolic shifts are associated with the mechanism of 4MU-mediated pro-catabolic inhibition, using molecular and metabolomics approaches, we examined whether bovine and human chondrocytes exhibit changes in the contribution of glycolysis and mitochondrial respiration to ATP production rates as well as in other factors that respond to or might drive these changes. Overexpression of either HA synthase-2 or 4MU effectively reduced dependence on glycolysis in chondrocytes, especially enhancing glycolysis use by interleukin-1ß (IL1ß)-activated chondrocytes. The reduction in glycolysis secondarily enhanced mitochondrial respiration in chondrocytes, which, in turn, rescued phospho-AMP-activated protein kinase (AMPK) levels in the activated chondrocytes. Other glycolysis inhibitors, unrelated to hyaluronan biosynthesis, namely 2-deoxyglucose and dichloroacetate, caused metabolic changes in chondrocytes equivalent to those elicited by 4MU and similarly protected both chondrocytes and cartilage explants. These results suggest that fluxes in UDP-hexoses alter metabolic energy pathways in cartilage.


Subject(s)
Chondrocytes/metabolism , Cytoprotection , Energy Metabolism , Hyaluronan Synthases/metabolism , Hymecromone/pharmacology , Acetylglucosamine/metabolism , Acylation , Adenylate Kinase/metabolism , Animals , Cartilage, Articular/drug effects , Cartilage, Articular/metabolism , Cattle , Cell Hypoxia/drug effects , Chondrocytes/drug effects , Chondrocytes/pathology , Cytoprotection/drug effects , Deoxyglucose/pharmacology , Dichloroacetic Acid/pharmacology , Energy Metabolism/drug effects , Female , Glycolysis/drug effects , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Inflammation/pathology , Interleukin-1beta/pharmacology , Male , Matrix Metalloproteinase 13/metabolism , Middle Aged , Phenotype , Phosphorylation/drug effects , Signal Transduction/drug effects
4.
J Biol Chem ; 294(37): 13562-13579, 2019 09 13.
Article in English | MEDLINE | ID: mdl-31270213

ABSTRACT

Osteoarthritis (OA) is a progressive degenerative disease of the joints caused in part by a change in the phenotype of resident chondrocytes within affected joints. This altered phenotype, often termed proinflammatory or procatabolic, features enhanced production of endoproteinases and matrix metallo-proteinases (MMPs) as well as secretion of endogenous inflammatory mediators. Degradation and reduced retention of the proteoglycan aggrecan is an early event in OA. Enhanced turnover of hyaluronan (HA) is closely associated with changes in aggrecan. Here, to determine whether experimentally increased HA production promotes aggrecan retention and generates a positive feedback response, we overexpressed HA synthase-2 (HAS2) in chondrocytes via an inducible adenovirus construct (HA synthase-2 viral overexpression; HAS2-OE). HAS2-OE incrementally increased high-molecular-mass HA >100-fold within the cell-associated and growth medium pools. More importantly, our results indicated that the HAS2-OE expression system inhibits MMP3, MMP13, and other markers of the procatabolic phenotype (such as TNF-stimulated gene 6 protein (TSG6)) and also enhances aggrecan retention. These markers were inhibited in OA-associated chondrocytes and in chondrocytes activated by interleukin-1ß (IL1ß), but also chondrocytes activated by lipopolysaccharide (LPS), tumor necrosis factor α (TNFα), or HA oligosaccharides. However, the enhanced extracellular HA resulting from HAS2-OE did not reduce the procatabolic phenotype of neighboring nontransduced chondrocytes as we had expected. Rather, HA-mediated inhibition of the phenotype occurred only in transduced cells. In addition, high HA biosynthesis rates, especially in transduced procatabolic chondrocytes, resulted in marked changes in chondrocyte dependence on glycolysis versus oxidative phosphorylation for their metabolic energy needs.


Subject(s)
Chondrocytes/metabolism , Hyaluronan Synthases/metabolism , Hyaluronic Acid/metabolism , Aggrecans/metabolism , Animals , Cartilage, Articular/metabolism , Cattle , Cell Adhesion Molecules/metabolism , Cells, Cultured , Humans , Hyaluronan Synthases/biosynthesis , Hyaluronan Synthases/genetics , Matrix Metalloproteinase 13/metabolism , Matrix Metalloproteinase 3/metabolism , Metabolomics/methods , Osteoarthritis/genetics , Osteoarthritis/metabolism , Primary Cell Culture
5.
Arch Biochem Biophys ; 665: 1-11, 2019 04 15.
Article in English | MEDLINE | ID: mdl-30776329

ABSTRACT

In this study we examined whether the action of simvastatin affects re-differentiation of passaged chondrocytes and if so, whether this was mediated via changes in cholesterol or cholesterol intermediates. Bovine articular chondrocytes, of varying passage number, human knee chondrocytes and rat chondrosarcoma chondrocytes were treated with simvastatin and examined for changes in mRNA and protein expression of markers of the chondrocyte phenotype as well as changes in cell shape, proliferation and proteoglycan production. In all three models, while still in monolayer culture, simvastatin treatment alone promoted changes in phenotype and morphology indicative of re-differentiation most prominent being an increase in SOX9 mRNA and protein expression. In passaged bovine chondrocytes, simvastatin stimulated the expression of SOX9, ACAN, BMP2 and inhibited the expression of COL1 and α-smooth muscle actin. Co-treatment of chondrocytes with simvastatin plus exogenous cholesterol-conditions that had previously reversed the inhibition on CD44 shedding, did not alter the effects of simvastatin on re-differentiation. However, the co-treatment of chondrocytes with simvastatin together with other pathway intermediates, mevalonate, geranylgeranylpyrophosphate and to a lesser extent, farnesylpyrophosphate, blocked the pro-differentiation effects of simvastatin. Treatment with simvastatin stimulated expression of SOX9 and COL2a and enhanced SOX9 protein in human OA chondrocytes. The co-treatment of OA chondrocytes with mevalonate or geranylgeranylpyrophosphate, but not cholesterol, blocked the simvastatin effects. These results lead us to conclude that the blocking of critical protein prenylation events is required for the positive effects of simvastatin on the re-differentiation of chondrocytes.


Subject(s)
Chondrocytes/drug effects , Simvastatin/pharmacology , Animals , Cattle , Cells, Cultured , Humans , Rats
6.
Matrix Biol ; 78-79: 32-46, 2019 05.
Article in English | MEDLINE | ID: mdl-29425696

ABSTRACT

The story of hyaluronan in articular cartilage, pericellular hyaluronan in particular, essentially is also the story of aggrecan. Without properly tethered aggrecan, the load bearing function of cartilage is compromised. The anchorage of aggrecan to the cell surface only occurs due to the binding of aggrecan to hyaluronan-with hyaluronan tethered either to a hyaluronan synthase or by multivalent binding to CD44. In this review, details of hyaluronan synthesis are discussed including how HAS2 production of hyaluronan is necessary for normal chondrocyte development and matrix assembly, how an abundance or deficit of pericellular hyaluronan alters chondrocyte metabolism, and whether hyaluronan size matters or changes with aging or disease. The biomechanical role and matrix assembly function of hyaluronan in addition to the functions of hyaluronidases are discussed. The turnover of hyaluronan is considered including mechanisms by which its turnover, at least in part, is mediated by endocytosis by chondrocytes and regulated by aggrecan degradation. Differences between turnover and clearance of newly synthesized hyaluronan and aggrecan versus the half-life of hyaluronan remaining within the inter-territorial matrix of cartilage are discussed. The release of neutral pH-acting hyaluronidase activity remains one unanswered question concerning the loss of cartilage hyaluronan in osteoarthritis. Signaling events driven by changes in hyaluronan-chondrocyte interactions may involve a chaperone function of CD44 with other receptors/cofactors as well as the changes in hyaluronan production functioning as a metabolic rheostat.


Subject(s)
Chondrocytes/cytology , Hyaluronan Synthases/metabolism , Hyaluronic Acid/metabolism , Animals , Chondrocytes/enzymology , Chondrocytes/metabolism , Endocytosis , Extracellular Matrix/metabolism , Half-Life , Humans
7.
Matrix Biol ; 56: 74-94, 2016 12.
Article in English | MEDLINE | ID: mdl-27094859

ABSTRACT

Hyaluronan (HA) plays an essential role in cartilage where it functions to retain aggrecan. Previous studies have suggested that aggrecan is anchored indirectly to the plasma membrane of chondrocytes via its binding to cell-associated HA. However, reagents used to test these observations such as hyaluronidase and HA oligosaccharides are short term and may have side activities that complicate interpretation. Using the CRISPR/Cas9 gene editing approach, a model system was developed by generating HA-deficient chondrocyte cell lines. HA synthase-2 (Has2)-specific single guide RNA was introduced into two different variant lines of rat chondrosarcoma chondrocytes; knockout clones were isolated and characterized. Two other members of the HA synthase gene family were expressed at very low relative copy number but showed no compensatory response in the Has2 knockouts. Wild type chondrocytes of both variants exhibited large pericellular matrices or coats extending from the plasma membrane. Addition of purified aggrecan monomer expanded the size of these coats as the proteoglycan became retained within the pericellular matrix. Has2 knockout chondrocytes lost all capacity to assemble a particle-excluding pericellular matrix and more importantly, no matrices formed around the knockout cells following the addition of purified aggrecan. When grown as pellet cultures so as to generate a bioengineered neocartilage tissue, the Has2 knockout chondrocytes assumed a tightly-compacted morphology as compared to the wild type cells. When knockout chondrocytes were transduced with Adeno-ZsGreen1-mycHas2, the cell-associated pericellular matrices were restored including the capacity to bind and incorporate additional exogenous aggrecan into the matrix. These results suggest that HA is essential for aggrecan retention and maintaining cell separation during tissue formation.


Subject(s)
Aggrecans/metabolism , Chondrocytes/enzymology , Hyaluronan Synthases/genetics , Hyaluronic Acid/metabolism , Animals , Base Sequence , CRISPR-Cas Systems , Cartilage, Articular/metabolism , Cell Line , Cell Proliferation , Chondrosarcoma , Gene Knockout Techniques , Hyaluronan Synthases/metabolism , Rats
8.
J Biol Chem ; 291(23): 12087-104, 2016 Jun 03.
Article in English | MEDLINE | ID: mdl-27129266

ABSTRACT

Depletion of the cartilage proteoglycan aggrecan is one of the earliest events that occurs in association with osteoarthritis. This loss is often accompanied by a coordinate loss in another glycosaminoglycan, hyaluronan. Chondrocytes experimentally depleted of cell-associated hyaluronan respond by switching to a pro-catabolic metabolism that includes enhanced production of endogenous inflammatory mediators and increased synthesis of matrix metalloproteinases. Hyaluronan turnover is also increased. Together, such a response provides for possible establishment of a self-perpetuating spiral of events that maintains or prolongs the pro-catabolic state. Chondrocytes or cartilage can also be activated by treatment with pro-inflammatory cytokines and mediators such as IL-1ß, TNFα, LPS, fibronectin fragments, and hyaluronan oligosaccharides. To determine the mechanism of chondrocyte activation due to hyaluronan loss, a depletion method was required that did not include degrading the hyaluronan. In recent years, several laboratories have used the coumarin derivative, 4-methylumbelliferone, as a potent inhibitor of hyaluronan biosynthesis, due in part to its ability to sequester intracellular UDP-glucuronic acid and inhibition of hyaluronan synthase transcription. However, contrary to our expectation, although 4-methylumbelliferone was indeed an inhibitor of hyaluronan biosynthesis, this depletion did not give rise to an activation of chondrocytes or cartilage. Rather, 4-methylumbelliferone directly and selectively blocked gene products associated with the pro-catabolic metabolic state of chondrocytes and did so through a mechanism preceding and independent of hyaluronan inhibition. These data suggest that 4-methylumbelliferone has additional useful applications to block pro-inflammatory cell activation events but complicates how it is used for defining functions related to hyaluronan.


Subject(s)
Chondrocytes/cytology , Hyaluronic Acid/metabolism , Cartilage, Articular/cytology , Cells, Cultured , Humans , Hymecromone/metabolism , Osteoarthritis/metabolism
9.
Matrix Biol ; 48: 42-54, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25864644

ABSTRACT

CD44 shedding occurs in osteoarthritic chondrocytes. Previous work of others has suggested that the hyaluronidase isoform HYAL2 has the capacity to bind to CD44, a binding that may itself induce CD44 cleavage. Experiments were developed to elucidate whether chondrocyte HYAL2: (1) was exposed on the extracellular plasma membrane of chondrocytes, (2) bound to CD44, (3) underwent shedding together with CD44 and lastly, (4) exhibited hyaluronidase activity within a near-neutral pH range. Enhancing CD44 shedding by IL-1ß resulted in a proportional increase in HYAL2 released from human and bovine chondrocytes into the medium. CD44 knockdown by siRNA also resulted in increased accumulation of HYAL2 in the media of chondrocytes. By hyaluronan zymography only activity at pH3.7 was observed and this activity was reduced by pre-treatment of chondrocytes with trypsin. CD44 and HYAL2 were found to co-immunoprecipitate, and to co-localize within intracellular vesicles and at the plasma membrane. Degradation of hyaluronan was visualized by agarose gel electrophoresis. With this approach, hyaluronidase activity could be observed at pH4.8 under assay conditions in which CD44 and HYAL2 binding remained intact; additionally, weak hyaluronidase activity could be observed at pH6.8 under these conditions. This study suggests that CD44 and HYAL2 are bound at the surface of chondrocytes. The release of HYAL2 when CD44 is shed could provide a mechanism for weak hyaluronidase activity to occur within the more distant extracellular matrix of cartilage.


Subject(s)
Cartilage, Articular/metabolism , Cell Adhesion Molecules/genetics , Chondrocytes/metabolism , Hyaluronan Receptors/genetics , Hyaluronic Acid/metabolism , Hyaluronoglucosaminidase/genetics , Osteoarthritis, Knee/genetics , Aged , Animals , Arthroplasty, Replacement, Knee , Cartilage, Articular/drug effects , Cartilage, Articular/pathology , Cattle , Cell Adhesion Molecules/antagonists & inhibitors , Cell Adhesion Molecules/metabolism , Cell Membrane/drug effects , Cell Membrane/metabolism , Chondrocytes/drug effects , Chondrocytes/pathology , Female , GPI-Linked Proteins/antagonists & inhibitors , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Gene Expression Regulation , Humans , Hyaluronan Receptors/metabolism , Hyaluronoglucosaminidase/antagonists & inhibitors , Hyaluronoglucosaminidase/metabolism , Hydrogen-Ion Concentration , Interleukin-1beta/pharmacology , Male , Middle Aged , Osteoarthritis, Knee/metabolism , Osteoarthritis, Knee/pathology , Primary Cell Culture , Protein Binding , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Signal Transduction , Trypsin/pharmacology
10.
J Biol Chem ; 290(15): 9555-70, 2015 Apr 10.
Article in English | MEDLINE | ID: mdl-25733665

ABSTRACT

In many cells hyaluronan receptor CD44 mediates the endocytosis of hyaluronan and its delivery to endosomes/lysosomes. The regulation of this process remains largely unknown. In most extracellular matrices hyaluronan is not present as a free polysaccharide but often is found in complex with other small proteins and macromolecules such as proteoglycans. This is especially true in cartilage, where hyaluronan assembles into an aggregate structure with the large proteoglycan termed aggrecan. In this study when purified aggrecan was added to FITC-conjugated hyaluronan, no internalization of hyaluronan was detected. This suggested that the overall size of the aggregate prevented hyaluronan endocytosis and furthermore that proteolysis of the aggrecan was a required prerequisite for local, cell-based turnover of hyaluronan. To test this hypothesis, limited C-terminal digestion of aggrecan was performed to determine whether a size range of aggrecan exists that permits hyaluronan endocytosis. Our data demonstrate that only limited degradation of the aggrecan monomer was required to allow for hyaluronan internalization. When hyaluronan was combined with partially degraded, dansyl chloride-labeled aggrecan, blue fluorescent aggrecan was also visualized within intracellular vesicles. It was also determined that sonicated hyaluronan of smaller molecular size was internalized more readily than high molecular mass hyaluronan. However, the addition of intact aggrecan to hyaluronan chains sonicated for 5 and 10 s reblocked their endocytosis, whereas aggregates containing 15-s sonicated hyaluronan were internalized. These data suggest that hyaluronan endocytosis is regulated in large part by the extracellular proteolytic processing of hyaluronan-bound proteoglycan.


Subject(s)
Endocytosis/drug effects , Hyaluronan Receptors/metabolism , Hyaluronic Acid/metabolism , Proteoglycans/pharmacology , Aggrecans/chemistry , Aggrecans/metabolism , Aggrecans/pharmacology , Animals , Cartilage, Articular/metabolism , Cattle , Cell Line, Tumor , Chondrocytes/metabolism , Chondrocytes/pathology , Electrophoresis, Agar Gel , Extracellular Matrix/metabolism , Microscopy, Fluorescence , Protein Aggregates , Protein Binding , Proteoglycans/chemistry , Proteoglycans/metabolism , Proteolysis , Rats
11.
Arthritis Rheumatol ; 66(6): 1547-58, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24497488

ABSTRACT

OBJECTIVE: Cell-matrix interactions promote cartilage homeostasis. We previously found that Smad1, the transcriptional modulator of the canonical bone morphogenetic protein 7 (BMP-7) pathway, interacted with the cytoplasmic domain of CD44, the principal hyaluronan receptor on chondrocytes. To elucidate the physiologic function of CD44-Smad1 interactions, as well as the role of hyaluronan, we studied the response of chondrocytes isolated from CD44(-/-) and BALB/c (wild-type [WT]) mice to stimulation with BMP-7. METHODS: In primary murine chondrocytes, CD44 expression was decreased by small interfering RNA (siRNA) transfection or was enhanced by plasmid transfection. Pericellular hyaluronan was removed by hyaluronidase treatment, or its endogenous synthesis was inhibited. Changes in response to BMP-7 stimulation were evaluated by Western blotting of Smad1 phosphorylation and aggrecan messenger RNA (mRNA) expression. RESULTS: Chondrocytes from CD44(-/-) mice and WT mice transfected with CD44 siRNA were less responsive than untransfected chondrocytes from WT mice to BMP-7. CD44(-/-) mouse chondrocytes transfected with pCD44 showed increased sensitivity to BMP-7. Significant increases in aggrecan mRNA were observed in WT mouse chondrocytes in response to 10 ng/ml of BMP-7, whereas at least 100 ng/ml of BMP-7 was required for CD44(-/-) mouse chondrocytes. However, in chondrocytes from CD44(-/-) and WT mice, hyaluronidase treatment decreased cellular responses to BMP-7. Treatment of both bovine and murine chondrocytes with 4-methylumbelliferone to reduce the synthesis of endogenous hyaluronan confirmed that hyaluronan promoted BMP-7 signaling. CONCLUSION: Taken together, these investigations into the mechanisms underlying BMP-7 signaling in chondrocytes revealed that while hyaluronan-dependent pericellular matrix is critical for BMP-7 signaling, the expression of CD44 promotes the cellular response to lower concentrations of BMP-7.


Subject(s)
Bone Morphogenetic Protein 7/pharmacology , Chondrocytes/drug effects , Hyaluronan Receptors/metabolism , Hyaluronic Acid/metabolism , Signal Transduction/drug effects , Aggrecans/metabolism , Animals , Cells, Cultured , Chondrocytes/metabolism , Chondrocytes/pathology , Hyaluronan Receptors/drug effects , Hyaluronan Receptors/genetics , Hyaluronic Acid/antagonists & inhibitors , Hyaluronoglucosaminidase/pharmacology , Mice , Mice, Inbred BALB C , Mice, Knockout , RNA, Small Interfering/pharmacology , Smad1 Protein/metabolism , Transfection
12.
Cartilage ; 5(3): 172-80, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25610529

ABSTRACT

OBJECTIVE: A recent report identified the small molecule kartogenin as a chondrogenic and chondroprotective agent. Since changes in hyaluronan metabolism occur during cartilage degeneration in osteoarthritis, we began studies to determine whether there was a connection between extracellular hyaluronan, CD44-hyaluronan interactions and the effects of kartogenin on articular chondrocytes. METHODS: Chondrocytes cultured in monolayers, bioengineered neocartilages, or cartilage explants were treated with kartogenin with or without stimulation by IL-1ß. Accumulation of matrix was visualized by a particle exclusion assay or by safranin O staining and release of sulfated glycosaminoglycans was determined. Production of aggrecanases and aggrecan G1-ITEGE neoepitope, fragmentation of CD44 and the SMAD1/5/8 signaling pathway were evaluated by western blotting. RESULTS: Kartogenin treatment enhanced chondrocyte pericellular matrix assembly and retention in the presence of IL-1ß. The chondroprotective effects of kartogenin on IL-1ß-induced release of sulfated glycosaminoglycans from articular cartilage explants, reduction in safranin O staining of neocartilage discs as well as a reduction in aggrecan G1-ITEGE neoepitope in chondrocyte and explant cartilage cultures were observed. Kartogenin partially blocked the IL-1ß-induced increased expression of ADAMTS-5. Additionally, kartogenin-treated articular chondrocytes exhibited a decrease in CD44 proteolytic fragmentation. However, kartogenin treatment did not enhance proteoglycan in control, non-IL-1ß-treated cultures. Similarly, kartogenin enhanced the SMAD1 phosphorylation but only following pretreatment with IL-1ß. CONCLUSION: These studies provide novel information on the chondroprotective function of kartogenin in adult articular cartilage. The effects of kartogenin are significant after activation of chondrocytic chondrolysis, which may occur following disruption of homeostasis maintained by hyaluronan-CD44 interactions.

13.
J Biol Chem ; 288(36): 25838-25850, 2013 Sep 06.
Article in English | MEDLINE | ID: mdl-23884413

ABSTRACT

The hyaluronan receptor CD44 undergoes sequential proteolytic cleavage at the cell surface. The initial cleavage of the CD44 extracellular domain is followed by a second intramembranous cleavage of the residual CD44 fragment, liberating the C-terminal cytoplasmic tail of CD44. In this study conditions that promote CD44 cleavage resulted in a diminished capacity to assemble and retain pericellular matrices even though sufficient non-degraded full-length CD44 remained. Using stable and transient overexpression of the cytoplasmic domain of CD44, we determined that the intracellular domain interfered with anchoring of the full-length CD44 to the cytoskeleton and disrupted the ability of the cells to bind hyaluronan and assemble a pericellular matrix. Co-immunoprecipitation assays were used to determine whether the mechanism of this interference was due to competition with actin adaptor proteins. CD44 of control chondrocytes was found to interact and co-immunoprecipitate with both the 65- and 130-kDa isoforms of ankyrin-3. Moreover, this interaction with ankyrin-3 proteins was diminished in cells overexpressing the CD44 intracellular domain. Mutating the putative ankyrin binding site of the transiently transfected CD44 intracellular domain diminished the inhibitory effects of this protein on matrix retention. Although CD44 in other cells types has been shown to interact with members of the ezrin/radixin/moesin (ERM) family of adaptor proteins, only modest interactions between CD44 and moesin could be demonstrated in chondrocytes. The data suggest that release of the CD44 intracellular domain into the cytoplasm of cells such as chondrocytes exerts a competitive or dominant-negative effect on the function of full-length CD44.


Subject(s)
Chondrocytes/metabolism , Hyaluronan Receptors/metabolism , Proteolysis , Animals , Ankyrins/genetics , Ankyrins/metabolism , Binding Sites , Cattle , Cell Line, Tumor , Chondrocytes/cytology , Humans , Hyaluronan Receptors/genetics , Hyaluronic Acid/genetics , Hyaluronic Acid/metabolism , Microfilament Proteins/genetics , Microfilament Proteins/metabolism , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Structure, Tertiary , Rats
14.
Biochem Biophys Res Commun ; 435(4): 733-9, 2013 Jun 14.
Article in English | MEDLINE | ID: mdl-23702485

ABSTRACT

During osteoarthritis there is a disruption and loss of the extracellular matrix of joint cartilage, composed primarily of type II collagen, aggrecan and hyaluronan. In young patients, autologous chondrocyte implantation can be used to repair cartilage defects. However, for more elderly patients with osteoarthritis, such a repair approach is contraindicated because the procedure requires a large expansion of autologous chondrocytes in vitro leading a rapid, perhaps irreversible, loss of the chondrocyte phenotype. This study investigates whether osteoarthritic chondrocytes obtained from older patients can be expanded in vitro and moreover, induced to re-activate their chondrocyte phenotype. A decrease in chondrocyte phenotype markers, collagen II, aggrecan and SOX9 mRNA was observed with successive expansion of cells in monolayer culture. However, chondrogenic induction in three-dimensional pellet culture successfully rescued the expression of all three marker genes to native levels, even with 4th passage cells-cells representing an approximate 625-fold expansion in cell number. This data supports the use of osteoarthritic cells for autologous implantation repair. In addition, another set of gene products were explored as useful markers of the chondrocyte phenotype. Differentiated primary chondrocytes exhibited a common pattern of hyaluronan synthase isoforms that changed upon cell expansion in vitro and, reverted back to the original pattern following pellet culture. Moreover, the change in isoform pattern correlated with changes in the molecular size of synthesized hyaluronan.


Subject(s)
Chondrocytes/metabolism , Chondrogenesis , Hyaluronic Acid/biosynthesis , Osteoarthritis, Knee/metabolism , Osteoarthritis, Knee/pathology , Aged , Aged, 80 and over , Cells, Cultured , Female , Humans , Male , Middle Aged
15.
J Orthop Res ; 30(4): 662-72, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21913222

ABSTRACT

Hyaluronan (HA) oligosaccharides were reported to have suppressive effects on various malignant tumors via disruption of receptor HA interactions. However, no studies have focused on the effects of HA oligosaccharides on bone metastasis of breast cancer. In this study, we clarified the effective size of HA oligosaccharides required to inhibit cell growth in the highly invasive breast cancer cell line, MDA-MB-231 cells. Based on the results of cell growth assay, we subsequently analyzed the effects of HA tetrasaccharides, HA decasaccharides, and high molecular weight HA on the other breast cancer cell behaviors in vitro and breast cancer bone metastasis in vivo. HA decasaccharides significantly inhibited cell growth, motility, and invasion, whereas tetrasaccharides did not. HAS2 mRNA expression was altered after the treatment with both tetrasaccharides and decasaccharides. Phosphorylation of Akt was suppressed after 1 h treatment with HA decasaccharides, and the effect was partially reversed by anti-CD44 monoclonal antibody. In vivo, local application of HA decasaccharides inhibited the expansion of osteolytic lesions in tibia on soft X-rays using mouse bone metastasis model of breast cancer. Histological analysis revealed HA accumulation in bone metastatic lesions was perturbed by decasaccharides. These results suggest that HA oligosaccharides suppressed progression of bone metastasis in breast cancer via interruption of endogenous HA-CD44 interaction, and as such, can be a novel therapeutic candidate to limit bone metastasis of breast cancer.


Subject(s)
Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Hyaluronic Acid/pharmacology , Oligosaccharides/pharmacology , Animals , Cell Division/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Disease Models, Animal , Female , Gene Expression Regulation, Neoplastic/drug effects , Glucuronosyltransferase/genetics , Humans , Hyaluronan Receptors/genetics , Hyaluronan Synthases , Mice , NIH 3T3 Cells , Neoplasm Invasiveness/pathology , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Tibia/pathology , Viscosupplements/pharmacology , Xenograft Model Antitumor Assays
16.
Arthritis Rheum ; 64(1): 187-97, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21905012

ABSTRACT

OBJECTIVE: Small hyaluronan (HA) oligosaccharides serve as competitive receptor antagonists to displace HA from the cell surface and induce cell signaling events. In articular chondrocytes, this cell signaling is mediated by the HA receptor CD44 and induces stimulation of genes involved in matrix degradation, such as matrix metalloproteinases (MMPs) as well as matrix repair genes including type II collagen, aggrecan, and HA synthase 2. The objective of this study was to determine changes in the expression and function of aggrecanases after disruption of chondrocyte CD44-HA interactions. METHODS: Bovine articular chondrocytes or bovine cartilage tissue was pretreated with a variety of inhibitors of major signaling pathways prior to the addition of HA oligosaccharides. Changes in aggrecanase were monitored by real-time reverse transcription-polymerase chain reaction and Western blot analyses of ADAMTS-4, ADAMTS-5, and aggrecan proteolytic fragments. To test the interactions between ADAMTS-4 and membrane type 4 MMP (MT4-MMP), protein lysates purified from stimulated chondrocytes were subjected to coimmunoprecipitation. RESULTS: Disruption of chondrocyte CD44-HA interactions with HA oligosaccharides induced the transcription of ADAMTS-4 and ADAMTS-5 in a time- and dose-dependent manner. The association of glycosyl phosphatidylinositol-anchored MT4-MMP with ADAMTS-4 was also induced in articular chondrocytes by HA oligosaccharides. Inhibition of the NF-κB pathway blocked HA oligosaccharide-mediated stimulation of aggrecanases. CONCLUSION: Disruptive changes in chondrocyte-matrix interactions by HA oligosaccharides induce matrix degradation and elevate aggrecanases via the activation of the NF-κB signaling pathway.


Subject(s)
Cartilage, Articular/drug effects , Chondrocytes/drug effects , Endopeptidases/metabolism , Hyaluronic Acid/pharmacology , Oligosaccharides/pharmacology , Viscosupplements/pharmacology , Aggrecans/genetics , Animals , Cartilage, Articular/metabolism , Cattle , Cells, Cultured , Chondrocytes/metabolism , Chromones/pharmacology , Collagen Type II/genetics , Drug Therapy, Combination , Endopeptidases/genetics , Flavonoids/pharmacology , Gene Expression Regulation, Enzymologic , Glucuronosyltransferase , Hyaluronan Receptors/metabolism , Imidazoles/pharmacology , Lactones/pharmacology , Morpholines/pharmacology , Pyridines/pharmacology , Sesquiterpenes, Eudesmane/pharmacology , Signal Transduction/drug effects
17.
J Biol Chem ; 285(46): 36216-24, 2010 Nov 12.
Article in English | MEDLINE | ID: mdl-20843796

ABSTRACT

Degradation of the cartilage proteoglycan aggrecan is one of the earliest events that occurs in association with osteoarthritis. Little is known concerning the fate of the residual N-terminal G1 domains of cleaved aggrecan; domains that remain bound to hyaluronan. In this study, 68-72-kDa bands representative of aggrecan G1 domains containing ITEGE(373) neoepitope were detected within a hyaluronidase-sensitive pool at the cell surface of bovine articular chondrocytes and within a hyaluronidase-insensitive, intracellular pool. To determine the mechanisms that contribute to this distribution, CD44 expression was knocked down by siRNA or function by CD44-DN. Both approaches prevented the retention and internalization of G1-ITEGE. Inhibition of CD44 transit into lipid rafts blocked the endocytosis of G1-ITEGE but not the retention at the cell surface. Chondrocytes derived from CD44 null mice also exhibited limited potential for retention and internalization of G1-VTEGE. The consequence of a lack of chondrocyte-mediated endocytosis of these domains in cartilage of the CD44 null mice was the accumulation of the degradation fragments within the tissue. Additionally, chondrocytes or fibroblasts derived from CD44 null mice exhibited little capacity for retention and internalization of exogenous G1-ITEGE derived from bovine cartilage explants. Bovine or wild type mouse fibroblasts were able to bind and internalize bovine-derived G1-ITEGE. Although several pathways are available for the clearance of these domains, CD44-mediated cellular internalization is the most prominent.


Subject(s)
Aggrecans/metabolism , Chondrocytes/metabolism , Epitopes/metabolism , Hyaluronan Receptors/metabolism , Aggrecans/genetics , Amino Acid Sequence , Animals , Binding Sites/genetics , Blotting, Western , Cartilage, Articular/cytology , Cattle , Cells, Cultured , Cholesterol/metabolism , Chondrocytes/cytology , Endocytosis/drug effects , Epitopes/genetics , Fibroblasts/cytology , Fibroblasts/metabolism , Hyaluronan Receptors/genetics , Interleukin-1beta/pharmacology , Lipoylation , Male , Membrane Microdomains/metabolism , Mice , Mice, Inbred BALB C , Mice, Knockout , Microscopy, Fluorescence , RNA Interference , Synovial Membrane/cytology
18.
Arthritis Rheum ; 62(5): 1338-48, 2010 May.
Article in English | MEDLINE | ID: mdl-20178130

ABSTRACT

OBJECTIVE: The hyaluronan receptor CD44 provides chondrocytes with a mechanism for sensing and responding to changes in the extracellular matrix. The purpose of this study was to document the fragmentation and loss of CD44 and to determine the likely mechanisms involved. METHODS: A polyclonal anti-CD44 cytotail antibody was generated to detect CD44 fragmentation by Western blot analysis. Chondrocytes were isolated from human or bovine articular cartilage. Primary articular chondrocytes were treated with interleukin-1beta (IL-1beta), hyaluronan oligosaccharides, or phorbol myristate acetate or were passaged and subcultured in monolayer to induce dedifferentiation. Conditions that altered the capacity of CD44 to transit into lipid rafts, or pharmacologic inhibitors of metalloproteinase or gamma-secretase activity were used to define the mechanism of fragmentation of CD44. RESULTS: Chondrocytes from osteoarthritic cartilage exhibited CD44 fragmentation as low molecular mass bands, corresponding to the CD44-EXT and CD44-ICD bands. Following dedifferentiation of chondrocytes or treatment of primary chondrocytes with hyaluronan oligosaccharides, IL-1beta, or phorbol myristate acetate, CD44 fragmentation was enhanced. Subsequent culture of the dedifferentiated chondrocytes in 3-dimensional alginate beads rescued the chondrocyte phenotype and diminished the fragmentation of CD44. Fragmentation of CD44 in chondrocytes was blocked in the presence of the metalloproteinase inhibitor GM6001 and the gamma-secretase inhibitor DAPT. CONCLUSION: CD44 fragmentation, consistent with a signature pattern reported for sequential metalloproteinase/gamma-secretase cleavage of CD44, is a common metabolic feature of chondrocytes that have undergone dedifferentiation in vitro and osteoarthritic chondrocytes. Transit of CD44 into lipid rafts may be required for its fragmentation.


Subject(s)
Chondrocytes/cytology , Chondrocytes/metabolism , Hyaluronan Receptors/metabolism , Osteoarthritis/pathology , Signal Transduction/physiology , Adjuvants, Immunologic/pharmacology , Amyloid Precursor Protein Secretases/antagonists & inhibitors , Amyloid Precursor Protein Secretases/metabolism , Animals , Antibodies/pharmacology , COS Cells , Carcinogens/pharmacology , Cattle , Cell Differentiation/physiology , Cells, Cultured , Chlorocebus aethiops , Chondrocytes/drug effects , Dipeptides/pharmacology , Extracellular Matrix/metabolism , Humans , Hyaluronan Receptors/immunology , Hyaluronic Acid/pharmacology , Interleukin-1beta/pharmacology , Membrane Microdomains/physiology , Metalloproteases/antagonists & inhibitors , Metalloproteases/metabolism , Osteoarthritis/immunology , Osteoarthritis/metabolism , Peptide Fragments/metabolism , Protease Inhibitors/pharmacology , Signal Transduction/drug effects , Tetradecanoylphorbol Acetate/pharmacology
19.
Am J Pathol ; 171(1): 274-86, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17591972

ABSTRACT

Numerous studies have demonstrated a correlation between hyaluronan expression and the malignant properties of various kinds of cancer, and inhibition of hyaluronan production causes decreased tumor growth. Hyaluronan oligosaccharides have been shown to inhibit several tumor cell types via disruption of receptor-hyaluronan interaction. However, few studies have addressed hyaluronan with respect to osteosarcoma. In this study, we examined the effects of exogenously added hyaluronan oligosaccharides on tumorigenicity of murine osteosarcoma cells, LM-8, and human osteoblastic osteosarcoma cells, MG-63. Moreover, the critical size of oligomers needed to inhibit malignant properties was defined. Fluorescent hyaluronan oligosaccharides accumulated both on the surface of cells and in the cytoplasm, and this retention was blocked by pretreatment with an anti-CD44 monoclonal antibody. Hyaluronan octasaccharides significantly inhibited cell viability and induced apoptosis as defined by cell proliferation and terminal deoxynucleotidyl transferase dUTP nick-end labeling assays, respectively. Octasaccharides also abrogated functional cell-associated matrices and significantly reduced the retention of endogenous hyaluronan. Further, octasaccharide treatment affected an inhibition of cell motility as well as cell invasiveness. Pretreatment of the cells with anti-CD44 antibody reduced the antitumor effect of the octasaccharides. In vivo, intratumoral injection of hyaluronan octasaccharides reduced the hyaluronan accumulation in local tumors, resulting in significant suppression of the formation of distant lung metastasis. Together these data suggest that hyaluronan oligosaccharides have potent antitumor effects functioning in part by the abrogation of hyaluronan-rich cell-associated matrices.


Subject(s)
Bone Neoplasms/metabolism , Bone Neoplasms/prevention & control , Hyaluronic Acid/pharmacology , Oligosaccharides/pharmacology , Osteosarcoma/metabolism , Osteosarcoma/prevention & control , Animals , Cell Movement , Cell Survival , Humans , Hyaluronan Receptors/physiology , Lung Neoplasms/secondary , Mice , Mice, Inbred C3H , Neoplasm Transplantation , Tumor Cells, Cultured
20.
J Biol Chem ; 281(26): 17952-60, 2006 Jun 30.
Article in English | MEDLINE | ID: mdl-16648633

ABSTRACT

Hyaluronan exerts a variety of biological effects on cells including changes in cell migration, proliferation, and matrix metabolism. However, the signaling pathways associated with the action of hyaluronan on cells have not been clearly defined. In some cells, signaling is induced by the loss of cell-hyaluronan interactions. The goal of this study was to use hyaluronan oligosaccharides as a molecular tool to explore the effects of changes in cell-hyaluronan interactions and determine the underlying molecular events that become activated. In this study, hyaluronan oligosaccharides induced the loss of extracellular matrix proteoglycan and collagen from cultured slices of normal adult human articular cartilage. This loss was coincident with an increased expression of matrix metalloproteinase (MMP)-13. MMP-13 expression was also induced in articular chondrocytes by hyaluronan (HA) hexasaccharides but not by HA tetrasaccharides nor high molecular weight hyaluronan. MMP-13 promoter-reporter constructs in CD44-null COS-7 cells revealed that both CD44-dependent and CD44-independent events mediate the induction of MMP-13 by hyaluronan oligosaccharides. Electromobility gel shift assays demonstrated the activation of chondrocyte NFkappaB by hyaluronan oligosaccharides. NFkappaB activation was also documented in C-28/I2 immortalized human chondrocytes by luciferase promoter assays and phosphorylation of IKK-alpha/beta. The link between activation of NFkappaB and MMP-13 induction by HA oligosaccharides was further confirmed through the use of the NFkappaB inhibitor helenalin. Inhibition of MAP kinases also demonstrated the involvement of p38 MAP kinase in the hyaluronan oligosaccharide induction of MMP-13. Our findings suggest that hyaluronan-CD44 interactions affect matrix metabolism via activation of NFkappaB and p38 MAP kinase.


Subject(s)
Chondrocytes/enzymology , Collagenases/metabolism , Hyaluronic Acid/pharmacology , NF-kappa B/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Cartilage, Articular/cytology , Cattle , Cell Line, Transformed , Cells, Cultured , Chondrocytes/cytology , Collagenases/genetics , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/physiology , Humans , Hyaluronan Receptors/metabolism , Matrix Metalloproteinase 13 , Oligosaccharides/pharmacology , RNA, Messenger/metabolism , Transcription, Genetic/drug effects , Transcription, Genetic/physiology , Transcriptional Activation/drug effects , Transcriptional Activation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...